Benefits
Bone health and fracture prevention
Severe vitamin D deficiency causes rickets in children and osteomalacia in adults — at this level, supplementation matters absolutely. Calcium + vitamin D combined reduces total fractures by about 15% and hip fractures by about 30% in older adults. Effect is strongest in people who are actually deficient and in institutionalized populations. Routine supplementation in community-dwelling older adults with adequate baseline levels does not reliably reduce fractures.
Cardiovascular events — supplementation does not prevent CVD
Despite strong observational links between low vitamin D and heart disease, the definitive randomized trials are negative. The largest trial (~26,000 adults, 2,000 IU/day for over 5 years) showed no reduction in heart attacks, strokes, or cardiovascular mortality. A second large trial replicated the null result. Vitamin D supplementation does not prevent cardiovascular disease in unselected adults — observational signals reflect confounding rather than causation.
Cancer — prevention failed, but cancer mortality may modestly drop
Vitamin D supplementation does not prevent cancer in healthy adults — the gold-standard trial was negative for total cancer incidence. There is a smaller signal that vitamin D may modestly reduce cancer death risk (about 17%), particularly when the first 1-2 years are excluded to account for latency. The mortality signal is suggestive but not definitive — best framed as 'don't expect cancer prevention, but a small cancer mortality benefit is plausible.'
Autoimmune disease prevention
This is the strongest current evidence for vitamin D supplementation in generally healthy adults. Vitamin D 2,000 IU/day combined with omega-3 reduces autoimmune disease incidence (rheumatoid arthritis, polymyalgia rheumatica, autoimmune thyroid disease, psoriasis) by about 22%. Effects appear over years, not weeks, suggesting cumulative immune modulation. More compelling rationale for routine supplementation than the bone or cardiovascular cases.
Fall prevention in older adults
Vitamin D 800-1,000 IU/day reduces falls in older adults, particularly those with documented deficiency or insufficiency. The USPSTF found insufficient evidence for fall prevention in non-deficient community-dwelling adults 65+ — meaning routine supplementation in already-replete older adults isn't validated. Reasonable component of fall-prevention strategy when deficiency is documented; not a guaranteed effect for all older adults.
Respiratory infections
Daily or weekly vitamin D supplementation reduces acute respiratory infection risk by about 12% overall, and by up to 70% in people with severe baseline deficiency. Important: bolus mega-dosing (single large doses) does not work — daily or weekly is the effective pattern. Effect is strongest in deficient individuals and modest in replete adults. Reasonable consideration during respiratory infection season, particularly in people with low sun exposure or known low vitamin D.
COVID-19 outcomes — keep status optimal, don't expect treatment
Low vitamin D was associated with worse COVID-19 outcomes in observational data, but supplementation trials have been mixed. Some forms (calcifediol in hospitalized patients) showed benefit; others were null. Practical takeaway: maintaining adequate vitamin D status year-round is reasonable as part of general health, but vitamin D is not a validated COVID-19 treatment and shouldn't substitute for vaccination or medical care.
Depression and mood — only matters if deficient
Vitamin D deficiency consistently tracks with depression in observational studies. But trials in non-deficient adults are negative — supplementing already-adequate levels doesn't improve mood. Effect appears to be real only when there's actual deficiency to correct, particularly in seasonal mood patterns or low-sun-exposure populations. Reasonable to optimize vitamin D status as part of comprehensive mood care; not a standalone antidepressant.
Mechanism of action
Metabolic Activation
Vitamin D (either D2 or D3) is first hydroxylated in the liver to form 25-hydroxyvitamin D [25(OH)D], the main circulating form. A second hydroxylation occurs primarily in the kidney, producing the active form, 1,25-dihydroxyvitamin D [1,25(OH)₂D, also called calcitriol]. These steps are catalyzed by cytochrome P450 enzymes (CYPs), such as CYP2R1 in the liver and CYP27B1 in the kidney
Genomic Actions
Calcitriol binds to the vitamin D receptor (VDR), a nuclear transcription factor present in many cell types. The VDR-calcitriol complex forms a heterodimer with the retinoid X receptor (RXR). This complex binds to vitamin D response elements (VDREs) in the DNA, regulating the transcription of hundreds of genes. These genes are involved in calcium and phosphate homeostasis, cell proliferation, differentiation, and immune function
Non-Genomic Actions
Some effects of vitamin D are too rapid to be explained by gene transcription, such as rapid calcium uptake in cells. These may be mediated by membrane-associated receptors and signaling pathways, including PDIA3
Clinical trials
Largest vitamin D primary prevention clinical trial to date — randomized double-blind placebo-controlled 2x2 factorial trial of vitamin D3 alongside omega-3 fatty acids. Published in NEJM. Conducted in US adults without known vitamin D deficiency at baseline.
25,871 US adults (men ≥50, women ≥55). 5.3-year intervention with vitamin D3 2,000 IU/day or placebo.
Primary endpoints (invasive cancer, major cardiovascular events) were negative — no significant difference vs placebo. Confirmed that vitamin D supplementation in adults without baseline deficiency does not prevent cardiovascular disease or primary cancer incidence. Established the strongest single counterpoint to widespread observational data linking low vitamin D to CV and cancer risk.
5-year prespecified secondary analysis of the VITAL trial examining incident autoimmune disease as an outcome. Published in BMJ (376:e066452). Autoimmune disease cases verified through medical record review and rheumatology consensus.
25,871 VITAL participants followed for new-onset autoimmune disease over 5 years.
Vitamin D 2,000 IU/day (with or without omega-3) reduced incident autoimmune disease by 22% vs placebo (HR 0.78, 95% CI 0.61-0.99). Combined vitamin D + omega-3 produced the strongest effect. Diseases captured included rheumatoid arthritis, polymyalgia rheumatica, autoimmune thyroid disease, and psoriasis. The strongest evidence base for routine vitamin D supplementation in generally healthy adults.
5-year randomized placebo-controlled trial in elderly Finnish adults comparing two vitamin D3 dose levels vs placebo. Published in American Journal of Clinical Nutrition. Northern latitude population with naturally lower sun exposure.
2,495 elderly Finnish adults (men ≥60, post-menopausal women ≥65). Three arms: placebo, 1,600 IU/day, or 3,200 IU/day for 5 years.
NO significant differences across the three arms for cardiovascular events, invasive cancer, or all-cause mortality. Reinforces the VITAL findings even at higher dose levels and in a more deficiency-prone northern-latitude population. Validates that the negative primary prevention findings aren't dose-limited or specific to one geography.
Individual participant data pooled analysis pooling raw data from randomized trials of vitamin D supplementation for prevention of acute respiratory infections. Published in BMJ. IPD analysis is the gold standard for meta-analytical methodology.
10,933 participants across 25 clinical trials. Various supplementation regimens (daily, weekly, bolus).
Daily or weekly vitamin D supplementation reduced acute respiratory infection risk by 12% overall (OR 0.88), with up to 70% reduction in those with severe baseline deficiency (25(OH)D <25 nmol/L). Importantly, bolus mega-dosing was not effective — daily or weekly patterns produced the benefit. Supports reasonable use of vitamin D during respiratory infection season, particularly in low-sun-exposure populations.
Evidence review and pooled analysis of fracture prevention trials in community-dwelling older adults. Published in JAMA. Distinguished community-dwelling from institutionalized populations, which has been an important confounding variable in earlier analyses.
51,145 community-dwelling older adults across 33 clinical trials.
Calcium, vitamin D, or the combination was not associated with reduced fracture incidence in community-dwelling older adults — contradicting long-held assumptions about routine supplementation for fracture prevention. Effect remains positive in institutionalized older adults and those with documented deficiency, but routine supplementation in healthy ambulatory older adults isn't validated.